Eliem Therapeutics, Inc. (NASDAQ:ELYM) Director Buys $49,952,816.64 in Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) Director Ra Capital Management, L.P. bought 13,008,546 shares of Eliem Therapeutics stock in a transaction on Thursday, June 27th. The shares were bought at an average cost of $3.84 per share, with a total value of $49,952,816.64. Following the acquisition, the director now directly owns 23,521,757 shares in the company, valued at $90,323,546.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Eliem Therapeutics Trading Down 0.8 %

Shares of ELYM stock traded down $0.06 during trading hours on Monday, reaching $7.05. The stock had a trading volume of 43,124 shares, compared to its average volume of 486,386. The stock’s fifty day simple moving average is $7.70 and its 200 day simple moving average is $4.58. Eliem Therapeutics, Inc. has a 12 month low of $2.35 and a 12 month high of $11.55. The firm has a market capitalization of $209.74 million, a PE ratio of -13.30 and a beta of -0.33.

Eliem Therapeutics (NASDAQ:ELYM) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.13) earnings per share for the quarter.

Institutional Investors Weigh In On Eliem Therapeutics

A hedge fund recently raised its stake in Eliem Therapeutics stock. BML Capital Management LLC raised its stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 0.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,193,742 shares of the company’s stock after buying an additional 13,742 shares during the period. Eliem Therapeutics comprises about 4.0% of BML Capital Management LLC’s investment portfolio, making the stock its 7th biggest position. BML Capital Management LLC owned 7.91% of Eliem Therapeutics worth $6,011,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 69.76% of the stock is owned by institutional investors.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.